CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
cangrelor +1 moredrug
Likely dose
cangrelor 30 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01766466
NCT01766466Phase 2Completed
CompareCT.gov

A Study of the Transition From Cangrelor to Ticagrelor, and Ticagrelor to Cangrelor in Patients With Coronary Artery Disease

The Medicines Company·interventional·Posted Jan 11, 2013·Updated May 19, 2014

In Brief

A Phase 2 clinical trial evaluating cangrelor and Ticagrelor for Coronary Artery Disease. Completed, enrolled 12 participants across 1 site.

Detailed Summary

To demonstrate that patients treated with cangrelor can be directly switched to oral ticagrelor and that patients treated with ticagrelor can be switched to cangrelor without a significant decrease in the extent of inhibition of platelet aggregation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 11, 2013
Enrollment StartJan 1, 2013
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 13.5 years ago

Interventions

cangrelordrug

Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.

Ticagrelordrug

Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion.